Akeso
9926.HKApprovedAkeso Inc. is a clinical-stage biopharmaceutical company headquartered in China, specializing in the research, development, and commercialization of innovative cancer immunotherapies. The company has built a robust pipeline of immune checkpoint inhibitors and bispecific antibodies, with several candidates in late-stage clinical trials. As a publicly traded company on the Hong Kong Stock Exchange, Akeso represents one of China's most promising biotech companies in the oncology space.
9926.HK · Stock Price
Historical price data
AI Company Overview
Akeso Inc. is a clinical-stage biopharmaceutical company headquartered in China, specializing in the research, development, and commercialization of innovative cancer immunotherapies. The company has built a robust pipeline of immune checkpoint inhibitors and bispecific antibodies, with several candidates in late-stage clinical trials. As a publicly traded company on the Hong Kong Stock Exchange, Akeso represents one of China's most promising biotech companies in the oncology space.
Technology Platform
Akeso focuses on developing immune checkpoint inhibitors and bispecific antibody therapeutics for cancer treatment, utilizing proprietary antibody discovery and engineering platforms.
Pipeline Snapshot
169169 drugs in pipeline, 37 in Phase 3
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Penpulimab + Investigator's choice of Chemotherapy | Hodgkin Disease Lymphoma | Phase 3 | |
| Cadonilimab + SOX chemotherapy + Placebo | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 3 | |
| Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium Fol... | Resectable Colon Cancer | Phase 3 | |
| AK104 + paclitaxel + carboplatin + cisplatin + bevacizumab + Placebo | Cervical Cancer | Phase 3 | |
| cadonilimab + pulocimab + paclitaxel + placebo | Gastric and Gastroesophageal Junction Adenocarcinoma | Phase 3 |
FDA Approved Drugs
1Opportunities
Risk Factors
Competitive Landscape
Akeso competes with established players like BeiGene, Innovent Biologics, and international pharmaceutical companies in the oncology immunotherapy space. The company differentiates through its focus on novel bispecific antibodies and strong position in the Chinese market.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile